Julie Dutil1, Lenin Godoy1, Rafael Rivera-Lugo2, Nelly Arroyo1, Elinette Albino1, Luis Negrón3, Alvaro N Monteiro4, Jaime L Matta1, Miguel Echenique5. 1. 1 Cancer Biology Division, Ponce Research Institute, Ponce Health Sciences University , Ponce, Puerto Rico . 2. 2 Department of Biology, University of Puerto Rico in Ponce , Ponce, Puerto Rico . 3. 3 Hematology-Oncology Program, VA Caribbean Healthcare System , San Juan, Puerto Rico . 4. 4 Cancer Epidemiology Program, H. Lee Moffitt Cancer Center and Research Institute , Tampa, Florida. 5. 5 Cancer Center, Auxilio Mutuo Hospital , San Juan, Puerto Rico .
Abstract
BACKGROUND: The role of deep intronic variants in hereditary cancer susceptibility has been largely understudied. Previously, the BRCA2 c.6937 + 594T>G variant has been shown to preferentially promote the inclusion of a 95 nucleotide cryptic exon and to introduce a premature termination codon. Our objective was to further assess the pathogenicity of the BRCA2 c.6937 + 594T>G deep intronic variant. PATIENTS AND METHODS: We examined the association between BRCA2 c.6937 + 594T>G and breast cancer (BC) risk in 464 BC cases and 497 noncancer controls from Puerto Rico. RESULTS: The overall frequency of the G allele was 2.1% in this population. There was no association between the TG/GG genotypes and BC risk in the uncorrected model and after correcting for confounders. There was only one carrier of the GG genotype. This individual did not have personal or family history of cancer and did not meet the National Comprehensive Cancer Network criteria for hereditary cancer genetic testing. CONCLUSIONS: Although previous work has demonstrated that the BRCA2 c.6937 + 594T>G variant affects splicing, this association study does not support a pathogenic role for the BRCA2 c.6937 + 594T>G intronic variant in breast and ovarian cancer syndrome susceptibility. Furthermore, it emphasizes the need to take into account multiple diverse populations in association studies for the assessment of variant pathogenicity.
BACKGROUND: The role of deep intronic variants in hereditary cancer susceptibility has been largely understudied. Previously, the BRCA2 c.6937 + 594T>G variant has been shown to preferentially promote the inclusion of a 95 nucleotide cryptic exon and to introduce a premature termination codon. Our objective was to further assess the pathogenicity of the BRCA2 c.6937 + 594T>G deep intronic variant. PATIENTS AND METHODS: We examined the association between BRCA2 c.6937 + 594T>G and breast cancer (BC) risk in 464 BC cases and 497 noncancer controls from Puerto Rico. RESULTS: The overall frequency of the G allele was 2.1% in this population. There was no association between the TG/GG genotypes and BC risk in the uncorrected model and after correcting for confounders. There was only one carrier of the GG genotype. This individual did not have personal or family history of cancer and did not meet the National Comprehensive Cancer Network criteria for hereditary cancer genetic testing. CONCLUSIONS: Although previous work has demonstrated that the BRCA2 c.6937 + 594T>G variant affects splicing, this association study does not support a pathogenic role for the BRCA2 c.6937 + 594T>G intronic variant in breast and ovarian cancer syndrome susceptibility. Furthermore, it emphasizes the need to take into account multiple diverse populations in association studies for the assessment of variant pathogenicity.
Entities:
Keywords:
BRCA2; hereditary breast and ovarian cancer syndrome; intronic variant; variant classification
Authors: J M Eggington; K R Bowles; K Moyes; S Manley; L Esterling; S Sizemore; E Rosenthal; A Theisen; J Saam; C Arnell; D Pruss; J Bennett; L A Burbidge; B Roa; R J Wenstrup Journal: Clin Genet Date: 2013-12-20 Impact factor: 4.438
Authors: David J Sanz; Alberto Acedo; Mar Infante; Mercedes Durán; Lucía Pérez-Cabornero; Eva Esteban-Cardeñosa; Enrique Lastra; Franco Pagani; Cristina Miner; Eladio A Velasco Journal: Clin Cancer Res Date: 2010-03-09 Impact factor: 12.531
Authors: D Ford; D F Easton; M Stratton; S Narod; D Goldgar; P Devilee; D T Bishop; B Weber; G Lenoir; J Chang-Claude; H Sobol; M D Teare; J Struewing; A Arason; S Scherneck; J Peto; T R Rebbeck; P Tonin; S Neuhausen; R Barkardottir; J Eyfjord; H Lynch; B A Ponder; S A Gayther; M Zelada-Hedman Journal: Am J Hum Genet Date: 1998-03 Impact factor: 11.025
Authors: S Neuhausen; T Gilewski; L Norton; T Tran; P McGuire; J Swensen; H Hampel; P Borgen; K Brown; M Skolnick; D Shattuck-Eidens; S Jhanwar; D Goldgar; K Offit Journal: Nat Genet Date: 1996-05 Impact factor: 38.330
Authors: Alberto Acedo; David J Sanz; Mercedes Durán; Mar Infante; Lucía Pérez-Cabornero; Cristina Miner; Eladio A Velasco Journal: Breast Cancer Res Date: 2012-05-25 Impact factor: 6.466
Authors: Julie Dutil; Volha A Golubeva; Alba L Pacheco-Torres; Hector J Diaz-Zabala; Jaime L Matta; Alvaro N Monteiro Journal: Breast Cancer Res Treat Date: 2015-11-12 Impact factor: 4.872
Authors: Hector J Diaz-Zabala; Ana P Ortiz; Lisa Garland; Kristine Jones; Cynthia M Perez; Edna Mora; Nelly Arroyo; Taras K Oleksyk; Miguel Echenique; Jaime L Matta; Michael Dean; Julie Dutil Journal: Cancers (Basel) Date: 2018-11-02 Impact factor: 6.639